Manish I Patel1, Caroline Kurek, Qihan Dong. 1. Department of Surgery, University of Sydney, Westmead, New South Wales, Australia. mpatel@med.usyd.edu.au
Abstract
PURPOSE: The arachidonic acid pathway incorporates phospholipase, cyclooxygenase, lipoxygenase and epoxygenase enzymes. This pathway has been shown to have a major role in the development and progression of a number of cancers, including prostate cancer. We discuss the current status of research of this pathway in the area of prostate cancer, ranging from preclinical in vitro studies to human clinical trials. MATERIALS AND METHODS: We performed an online search of the current and past peer reviewed literature on prostate cancer and arachidonic acid, phospholipase, cyclooxygenase, lipoxygenase, epoxygenase, platelet activating factor, prostaglandin and eicosanoid. We retrieved and evaluated all full-length articles published in English from the 1980s to January 2007. RESULTS: Epidemiological evidence suggested that nonsteroidal anti-inflammatory drugs may decrease the risk of prostate cancer. This effect, presumably through the inhibition of cyclooxygenase-2, has been validated in preclinical studies. Cyclooxygenase-2 inhibition has also decreased the rate of prostate specific antigen increase in men with biochemical recurrence after treatment for prostate cancer. Although lipoxygenase and secretory phospholipase A2 inhibition was also effective for decreasing prostate cancer growth in preclinical studies, to our knowledge these strategies have not yet been used in clinical trials. Cytosolic phospholipase A2, platelet activating factor and epoxygenase need further investigation to determine a role in prostate cancer. CONCLUSIONS: Evolving data suggest a significant role for some areas of the arachidonic acid pathway in prostate cancer. Inhibiting 1 or a number of these enzymes in combination may hold promise for future prostate cancer treatment.
PURPOSE: The arachidonic acid pathway incorporates phospholipase, cyclooxygenase, lipoxygenase and epoxygenase enzymes. This pathway has been shown to have a major role in the development and progression of a number of cancers, including prostate cancer. We discuss the current status of research of this pathway in the area of prostate cancer, ranging from preclinical in vitro studies to human clinical trials. MATERIALS AND METHODS: We performed an online search of the current and past peer reviewed literature on prostate cancer and arachidonic acid, phospholipase, cyclooxygenase, lipoxygenase, epoxygenase, platelet activating factor, prostaglandin and eicosanoid. We retrieved and evaluated all full-length articles published in English from the 1980s to January 2007. RESULTS: Epidemiological evidence suggested that nonsteroidal anti-inflammatory drugs may decrease the risk of prostate cancer. This effect, presumably through the inhibition of cyclooxygenase-2, has been validated in preclinical studies. Cyclooxygenase-2 inhibition has also decreased the rate of prostate specific antigen increase in men with biochemical recurrence after treatment for prostate cancer. Although lipoxygenase and secretory phospholipase A2 inhibition was also effective for decreasing prostate cancer growth in preclinical studies, to our knowledge these strategies have not yet been used in clinical trials. Cytosolic phospholipase A2, platelet activating factor and epoxygenase need further investigation to determine a role in prostate cancer. CONCLUSIONS: Evolving data suggest a significant role for some areas of the arachidonic acid pathway in prostate cancer. Inhibiting 1 or a number of these enzymes in combination may hold promise for future prostate cancer treatment.
Authors: Paula Vainio; Santosh Gupta; Kirsi Ketola; Tuomas Mirtti; John-Patrick Mpindi; Pekka Kohonen; Vidal Fey; Merja Perälä; Frank Smit; Gerald Verhaegh; Jack Schalken; Kalle A Alanen; Olli Kallioniemi; Kristiina Iljin Journal: Am J Pathol Date: 2011-02 Impact factor: 4.307
Authors: Daine T Bennett; Xin-Sheng Deng; Jessica A Yu; Marshall T Bell; David C Mauchley; Xianzhong Meng; T Brett Reece; David A Fullerton; Michael J Weyant Journal: Ann Thorac Surg Date: 2014-06-10 Impact factor: 4.330
Authors: Piotr Ruchala; Mohamad Navab; Chun-Ling Jung; Susan Hama-Levy; Ewa D Micewicz; Hai Luong; Jonathan E Reyles; Shantanu Sharma; Alan J Waring; Alan M Fogelman; Robert I Lehrer Journal: PLoS One Date: 2010-04-14 Impact factor: 3.240
Authors: Manish I Patel; Jaskirat Singh; Marzieh Niknami; Caroline Kurek; Mu Yao; Sasa Lu; Fiona Maclean; Nicholas J C King; Michael H Gelb; Kieran F Scott; Pamela J Russell; John Boulas; Qihan Dong Journal: Clin Cancer Res Date: 2008-12-15 Impact factor: 12.531
Authors: Hiromi Hanaka; Sven-Christian Pawelzik; John Inge Johnsen; Marija Rakonjac; Kan Terawaki; Agnes Rasmuson; Baldur Sveinbjörnsson; Martin C Schumacher; Mats Hamberg; Bengt Samuelsson; Per-Johan Jakobsson; Per Kogner; Olof Rådmark Journal: Proc Natl Acad Sci U S A Date: 2009-10-21 Impact factor: 11.205
Authors: Colette Galet; Kiran Gollapudi; Sevan Stepanian; Joshua B Byrd; Susanne M Henning; Tristan Grogan; David Elashoff; David Heber; Jonathan Said; Pinchas Cohen; William J Aronson Journal: Cancer Prev Res (Phila) Date: 2013-10-29